Ausgabe 3/2011
Inhalt (12 Artikel)
Prognostic factors in desmoid tumours: an example of translational oncology
Soledad Gallego Melcón
Mechanism of hot flashes
Santiago Vilar-González, Alberto Pérez-Rozos, Ruben Cabanillas-Farpón
Direct antitumour activity of zoledronic acid: preclinical and clinical data
Joaquim Bosch-Barrera, Sofía D. Merajver, Javier A. Menéndez, Catherine Van Poznak
New technologies in cancer. Protein microarrays for biomarker discovery
Sergio Matarraz, María González-González, María Jara, Alberto Orfao, Manuel Fuentes
Treatment recommendations for metastatic colorectal cancer
Enrique Aranda, Albert Abad, Alfredo Carrato, Andrés Cervantes, Jesús García-Foncillas, Pilar García Alfonso, Rocío García Carbonero, Auxiliadora Gómez España, Josep M. Tabernero, Eduardo Díaz-Rubio
Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer
Cristina Grávalos, Carlos Gómez-Martín, Fernando Rivera, Inmaculada Alés, Bernardo Queralt, Antonia Márquez, Ulpiano Jiménez, Vicente Alonso, Rocío García-Carbonero, Javier Sastre, Ramon Colomer, Hernán Cortés-Funes, Antonio Jimeno
Spinal cord astrocytoma: multidisciplinary experience
M. Isabel Tovar Martín, Escarlata López Ramírez, Enrique Saura Rojas, Gregorio Arregui Castillo, Mercedes Zurita Herrera
Multimodal treatment of desmoid tumours: the significance of local control
Bella Pajares, Esperanza Torres, Begoña Jiménez, Isabel Sevilla, Ana Rodríguez, José Manuel Rico, José Manuel Trigo, Emilio Alba
Alternate PAX3 and PAX7 C-terminal isoforms in myogenic differentiation and sarcomagenesis
Elizabeth Charytonowicz, Igor Matushansky, Mireia Castillo-Martin, Todd Hricik, Carlos Cordon-Cardo, Mel Ziman
Circulating tumour cells in peripheral blood: potential impact on breast cancer outcome
María José Serrano, José Antonio Lorente, Miguel Delgado Rodríguez, Ana Fernández, Mónica Fernández, Capilla de la Torre, Jaime Fernández Izquierdo, Pedro Sánchez Rovira
Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?
Carmen Balañá, Olatz Etxaniz, Cristina Bugés, Alex Martínez